No Data
Haoyuan Pharmaceuticals (688131.SH): "Haoyuan convertible bonds" will open for subscription on November 28.
Haoyuan Pharmaceutical (688131.SH) announced that the convertible corporate bonds issued this time are referred to as 'Haoyuan Convertible...'
Haoyuan Pharmaceuticals (688131): Revenue growth remains steady, with continuous improvement in profit margin.
The core point is that the company achieved revenue of 1.62 billion yuan in the first three quarters of 2024, a year-on-year increase of 17.6%. Achieved a net income attributable to the parent company of 0.143 billion yuan, a year-on-year increase of 21.3%. Benefiting from the rapid growth of the front-end business, the company
Haoyuan Pharmaceutical (688131): Meeting expectations, accelerating overseas expansion of front-end business.
Event: The company released the third quarter report of 2024, achieving revenue of 1.619 billion yuan in the first three quarters of 2024 (+17.65% year-on-year), with a net income attributable to the parent company of 0.143 billion yuan (+21.31% year-over-year), excluding non-recurring items.
Shanghai Haoyuan Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Haoyuan Pharmaceutical (688131.SH): the net income in the first three quarters was 0.143 billion yuan, with a year-on-year growth of 21.31%.
On October 29th, Haoyuan Medicine (688131.SH) announced that in the first three quarters of 2024, it achieved total operating income of 1.619 billion yuan, an increase of 17.65% year-on-year; the net income attributable to the parent company's shareholders was 0.143 billion yuan, a year-on-year increase of 21.31%; and the basic earnings per share was 0.68 yuan.
October 29th A-share investment lightning rod︱West Pharmaceutical: Shareholders China National Pharmaceutical Group and Hangzhou Chuanhe plan to jointly reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.
No Data
No Data